Orexigen Therapeutics, Inc. is a public American pharmaceutical company focused on development of treatments for obesity.

[1] The company is based in La Jolla, California and was established by Eckard Weber in 2002.

[1] As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX.

[1] The company has a single product, Contrave, approved for use in the United States in 2014.

[3] Observation of the market performance of Qsymia and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering.